Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
Remembering former ICR Chief Executive Professor Peter Garland
The ICR reflects on the legacy of Professor Peter Garland CBE, who served as Chief Executive from 1989 to 1999 and died on 5 March.
.png?sfvrsn=38d02ad6_1 "PW head and shoulders in garden_expand.jpg (1)")
The ICR’s Professor Paul Workman elected Fellow of the American Association of Cancer Research Academy
The Institute of Cancer Research, London, is delighted to announce that Professor Paul Workman has been elected as a Fellow of The American Association for Cancer Research (AACR) Academy.
New collaboration to advance innovative drugs for aggressive childhood brain tumours
Scientists at The Institute of Cancer Research, London, are partnering with Revolver Therapeutics to accelerate the development of pioneering drugs for treating incurable childhood brain tumours.
£1.5million funding boost to help unlock the genetic secrets of aggressive neuroblastoma
Scientists from The Institute of Cancer Research, London, will be part of a team of international researchers who have secured funding to study the genetic secrets of childhood cancer neuroblastoma.